Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential - Scorecard - MDSpire

Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential

  • By

  • Giovanni Francesco Spatola

  • Alessandro Pitruzzella

  • Antonino Gioacchino Listro

  • Carla Valenti

  • Mariaelena Scalisi

  • Federica Milia

  • Paolo Listro

  • Flavia Zingales

  • Giulio Maria Ferranti

  • Marta Listro

  • Beatrice Belmonte

  • Domiziana Picone

  • Giorgia Intili

  • Maria Laura Uzzo

  • May 4, 2026

  • 0 min

Share

Clinical Scorecard: Expression of Matrix Metalloproteinases in Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma: Implications for Diagnosis and Prognosis

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients aged 40-50 years with skin cancer, specifying tumor stage or type.
Care Setting

Key Highlights

  • highlight_2

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider targeting MMP-3 and MMP-14 in therapeutic strategies for skin cancer, including combination therapies.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        MMP-3 and MMP-14 may be targeted for therapeutic interventions, noting potential side effects.

        Clinical Best Practices

        • Incorporate MMP expression analysis in the evaluation of skin cancer patients, with follow-up care recommendations.

        References

        Original Source(s)

        Matrix metalloproteinase expression in basal cell carcinoma, squamous carcinoma, and melanoma: diagnostic and prognostic potential

        • by Giovanni Francesco Spatola, Alessandro Pitruzzella, Antonino Gioacchino Listro, Carla Valenti, Mariaelena Scalisi, Federica Milia, Paolo Listro, Flavia Zingales, Giulio Maria Ferranti, Marta Listro, Beatrice Belmonte, Domiziana Picone, Giorgia Intili, Maria Laura Uzzo

        • May 4, 2026

        Related Content

        Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

        Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

        Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer